Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intralesional methotrexate versus triamcinolone for nail psoriasis
IRCT20140212016557N7Phase 3Completed
- Sponsor
- Shiraz University of Medical Sciences
- Start
- May 2021
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, single-blind trial of methotrexate and triamcinolone in nail psoriasis (2 arms), sponsored by Shiraz University of Medical Sciences. Primary endpoint: Severity of nail involvement with psoriasis at week 23. Started May 2021; status: completed.
02
Drugs
methotrexatetriamcinolone
03
Conditions
nail psoriasis
Beyond the preview
Go deeper on IRCT20140212016557N7.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20140212016557N7.